mogamulizumab 🐶 Veterinary Use | Indications/Contra | FAERs-F | FAERs-M | Orange Bk | BioActivity |

Stem definition	Drug id	CAS RN
humanized origin	5031	1159266-37-1

Description:

Molecule

Description

Synonyms:

mogamulizumab-kpkc
AMG-761
KM8761
mogamulizumab
mogamulizumab (genetical recombination)
poteligeo
KW-0761

a defucosylated humanized anti-CCR4 antibody under phase I clinical trials (2010)

Molecular weight:
Formula:
CLOGP:
LIPINSKI: None
HAC: None
HDO: None
TPSA:
ALOGS:
ROTB: None

Drug dosage:

None

ADMET properties:

None

Approvals:

Date	Agency	Company	Orphan
Aug. 8, 2018	FDA	KYOWA KIRIN
March 30, 2012	PMDA	Kyowa Hakko Kirin Co., Ltd.

FDA Adverse Event Reporting System (Female)

None

FDA Adverse Event Reporting System (Male)

MedDRA adverse event term	Likelihood ratio	Likelihood ratio threshold	Patients taking drug having adverse event	Patients taking drug not having adverse event	Patients not taking drug having adverse event	Patients not taking drug not having adverse event
Diffuse large B-cell lymphoma	59.60	58.97	13	226	7357	34949335

FDA Adverse Event Reporting System (Geriatric)

MedDRA adverse event term	Likelihood ratio	Likelihood ratio threshold	Patients taking drug having adverse event	Patients taking drug not having adverse event	Patients not taking drug having adverse event	Patients not taking drug not having adverse event
Diffuse large B-cell lymphoma	55.74	50.22	13	427	12136	79731812
Peripheral T-cell lymphoma unspecified stage III	51.19	50.22	5	435	7	79743941

FDA Adverse Event Reporting System (Pediatric)

None

Pharmacologic Action:

Source	Code	Description
ATC	L01FX09	ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS ANTINEOPLASTIC AGENTS MONOCLONAL ANTIBODIES AND ANTIBODY DRUG CONJUGATES Other monoclonal antibodies and antibody drug conjugates
FDA CS	M0001357	Antibodies, Monoclonal
MeSH PA	D000970	Antineoplastic Agents
FDA EPC	N0000193863	Monoclonal Antibody
FDA EPC	N0000193866	Chemokine Receptor Type 4 Interaction
FDA MoA	N0000193867	Chemokine Receptor Type 4 Interactions

Drug Use | Suggest Off label Use Form| |View source of the data|

Disease	Relation	SNOMED_ID	DOID
Peripheral T-cell lymphoma	indication	109977009
Mycosis fungoides	indication	118618005
Primary cutaneous T-cell lymphoma	indication	400122007

🐶 Veterinary Drug Use

None

🐶 Veterinary products

None

Acid dissociation constants calculated using MoKa v3.0.0

None

Orange Book patent data (new drug applications)

None

Orange Book exclusivity data (new drug applications)

None

Bioactivity Summary:

Target	Class	Pharos	UniProt	Action	Type	Activity value (-log[M])	Mechanism action	Bioact source	MoA source
C-C chemokine receptor type 4	GPCR	P51679	CCR4_HUMAN	ANTIBODY BINDING				SCIENTIFIC LITERATURE	SCIENTIFIC LITERATURE

External reference:

ID	Source
YI437801BE	UNII
4037780	VANDF
4037781	VANDF
C2987603	UMLSCUI
CHEMBL1743041	ChEMBL_ID
D09761	KEGG_DRUG
DB12498	DRUGBANK_ID
9374	INN_ID
C549035	MESH_SUPPLEMENTAL_RECORD_UI
6477	IUPHAR_LIGAND_ID
2054068	RXNORM
287441	MMSL
34735	MMSL
34736	MMSL
d08855	MMSL
017677	NDDF
773521007	SNOMEDCT_US
773522000	SNOMEDCT_US

Pharmaceutical products:

Product	Category	Ingredients	NDC	Form	Quantity	Route	Marketing	Label
POTELIGEO	HUMAN PRESCRIPTION DRUG LABEL	1	42747-761	INJECTION	4 mg	INTRAVENOUS	BLA	27 sections
POTELIGEO	HUMAN PRESCRIPTION DRUG LABEL	1	42747-761	INJECTION	4 mg	INTRAVENOUS	BLA	27 sections
POTELIGEO	HUMAN PRESCRIPTION DRUG LABEL	1	42747-761	INJECTION	4 mg	INTRAVENOUS	BLA	27 sections